

SUPPLEMENTARY MATERIALS

Table S1. Characteristics of symptomatic UTI persons

	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6
Sex/Age (yr)	Male/48	Male/58	Male/65	Male/25	Male/31	Male/63
Level of injury/AIS	C4/B	C2/D	C6/A	C4/A	T1/A	C2/D
Duration (mo)	11	3	4	4	4	8
Underlying disease	None	None	Diabetes, hypertension	None	None	Hypertension
History of UTI within 1 month	1 month ago	None	None	None	None	None
Bladder emptying method	Suprapubic indwelling catheter	Voiding without catheter	Intermittent catheterization by caregiver	Transurethral indwelling catheter	Transurethral indwelling catheter	Voiding without catheter
Bladder medication	Propiverine 20 mg qd	None	None	None	Oxybutynin 5 mg bid	Tamsulosin 0.4 mg hs
UTI symptom (post-UDS)	Fever	Fever	Fever	Fever	Fever	Fever
Urine analysis & culture						
Pre-pyuria (/HPF)	>20	5-9	>20	10-19	>20	Sterile
Post-pyuria (/HPF)	>20	>20	10-19	>20	10-19	10-19
Pre-bacteriuria	<i>P. aeruginosa</i>	Sterile	<i>E. coli</i> (ESBL)	<i>S. maltophilia</i>	<i>A. lwoffii</i>	Sterile
Post-bacteriuria	<i>P. aeruginosa</i>	Sterile	<i>E. coli</i> (ESBL)	Sterile	Sterile	<i>K. pneumoniae</i> (ESBL)
UDS findings						
Maximal detrusor pressure (mmHg)	10	57	6	17	30	8
Bladder compliance (mL/cmH ₂ O)	82.5	64.5	88.8	34	25.6	178.2
Bladder capacity (mL)	550	550	600	700	550	550
Antibiotics	Ciprofloxacin	Ciprofloxacin	Ciprofloxacin	Ciprofloxacin	Ciprofloxacin	Ciprofloxacin

UTI, urinary tract infection; UDS, urodynamic study; AIS, American Spinal cord Injury Association Impairment Scale; HPF, house field units; ESBL, extended spectrum β -lactamase.